NO321329B1 - Fremgangsmate til a fastsette kjemoterapi for pasienter som er HIV positive, basert pa fenotypisk legemiddelfolsomhet hos pasientens HIV-stammer - Google Patents
Fremgangsmate til a fastsette kjemoterapi for pasienter som er HIV positive, basert pa fenotypisk legemiddelfolsomhet hos pasientens HIV-stammer Download PDFInfo
- Publication number
- NO321329B1 NO321329B1 NO19983300A NO983300A NO321329B1 NO 321329 B1 NO321329 B1 NO 321329B1 NO 19983300 A NO19983300 A NO 19983300A NO 983300 A NO983300 A NO 983300A NO 321329 B1 NO321329 B1 NO 321329B1
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- chimeric
- inhibitors
- patient
- sensitivity
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 77
- 230000035945 sensitivity Effects 0.000 title claims abstract description 40
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims description 60
- 239000003814 drug Substances 0.000 title claims description 60
- 239000003112 inhibitor Substances 0.000 claims abstract description 80
- 241000700605 Viruses Species 0.000 claims abstract description 46
- 108700004029 pol Genes Proteins 0.000 claims abstract description 28
- 101150088264 pol gene Proteins 0.000 claims abstract description 28
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 230000000007 visual effect Effects 0.000 claims abstract description 3
- 102100034343 Integrase Human genes 0.000 claims description 65
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 38
- 108091005804 Peptidases Proteins 0.000 claims description 24
- 239000013612 plasmid Substances 0.000 claims description 19
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 18
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 18
- 238000001890 transfection Methods 0.000 claims description 18
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 17
- 239000004365 Protease Substances 0.000 claims description 14
- 239000012620 biological material Substances 0.000 claims description 13
- 239000002777 nucleoside Substances 0.000 claims description 13
- 230000002441 reversible effect Effects 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 12
- 230000008901 benefit Effects 0.000 claims description 11
- 238000010276 construction Methods 0.000 claims description 11
- 101150104269 RT gene Proteins 0.000 claims description 9
- 229940124524 integrase inhibitor Drugs 0.000 claims description 9
- 239000002850 integrase inhibitor Substances 0.000 claims description 9
- 108020000999 Viral RNA Proteins 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 7
- 238000004520 electroporation Methods 0.000 claims description 6
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims description 6
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims description 6
- 108010061833 Integrases Proteins 0.000 claims description 5
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 229960001936 indinavir Drugs 0.000 claims description 5
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 5
- 238000010839 reverse transcription Methods 0.000 claims description 5
- 229960000311 ritonavir Drugs 0.000 claims description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 5
- ZNFFMCYSMBXZQU-NSHDSACASA-N 5-chloro-8-methyl-7-(3-methyl-but-2-enyl)-6,7,8,9-tetrahydro-2h-2,7,9a-triaza-benzo[cd]azulene-1-thione Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=C(Cl)C1=C32 ZNFFMCYSMBXZQU-NSHDSACASA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229950006243 loviride Drugs 0.000 claims description 4
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001852 saquinavir Drugs 0.000 claims description 4
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 4
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000001788 irregular Effects 0.000 claims description 3
- 229960000689 nevirapine Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 229950011282 tivirapine Drugs 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 238000000423 cell based assay Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 27
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 abstract description 4
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 93
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 230000035772 mutation Effects 0.000 description 16
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 16
- 229960002555 zidovudine Drugs 0.000 description 15
- 230000008859 change Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 230000006798 recombination Effects 0.000 description 12
- 238000005215 recombination Methods 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000009104 chemotherapy regimen Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- 238000002955 isolation Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000001566 pro-viral effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 4
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 101710203526 Integrase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- -1 ddl Chemical compound 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940124821 NNRTIs Drugs 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102220500387 Neutral and basic amino acid transport protein rBAT_M41Y_mutation Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003084 hiv integrase inhibitor Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940063627 rescriptor Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 102220011161 rs727504317 Human genes 0.000 description 1
- 102200069353 rs8103142 Human genes 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940098802 viramune Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96200175 | 1996-01-26 | ||
| PCT/IB1997/000071 WO1997027480A1 (en) | 1996-01-26 | 1997-01-24 | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983300D0 NO983300D0 (no) | 1998-07-16 |
| NO983300L NO983300L (no) | 1998-09-25 |
| NO321329B1 true NO321329B1 (no) | 2006-04-24 |
Family
ID=8223611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983300A NO321329B1 (no) | 1996-01-26 | 1998-07-16 | Fremgangsmate til a fastsette kjemoterapi for pasienter som er HIV positive, basert pa fenotypisk legemiddelfolsomhet hos pasientens HIV-stammer |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US6221578B1 (pl) |
| EP (1) | EP0877937B1 (pl) |
| KR (1) | KR100495690B1 (pl) |
| CN (2) | CN1209875A (pl) |
| AT (1) | ATE217971T1 (pl) |
| AU (1) | AU717755B2 (pl) |
| BG (1) | BG102710A (pl) |
| BR (1) | BR9707204A (pl) |
| CZ (1) | CZ292899B6 (pl) |
| DE (1) | DE69712731T2 (pl) |
| ES (1) | ES2177922T3 (pl) |
| HU (1) | HU226203B1 (pl) |
| IL (1) | IL125442A (pl) |
| IS (1) | IS4799A (pl) |
| NO (1) | NO321329B1 (pl) |
| NZ (1) | NZ325912A (pl) |
| PL (1) | PL186473B1 (pl) |
| SK (1) | SK283878B6 (pl) |
| TR (1) | TR199801443T2 (pl) |
| WO (1) | WO1997027480A1 (pl) |
| ZA (1) | ZA97669B (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0656887T3 (da) | 1992-08-25 | 1999-07-05 | Searle & Co | Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser |
| US20030220276A1 (en) * | 1995-05-16 | 2003-11-27 | Opendra Narayan | HIV vaccine and method of use |
| US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US20070010471A1 (en) * | 1997-05-02 | 2007-01-11 | Opendra Narayan | HIV DNA vaccine |
| JP2001512036A (ja) * | 1997-07-30 | 2001-08-21 | バイアラジック・インコーポレーテッド | 抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法 |
| BR9911600A (pt) * | 1998-05-26 | 2001-02-13 | Virologic Inc | Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo |
| MXPA01012270A (es) * | 1999-05-28 | 2003-06-24 | Virco Nv | Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos. |
| US6800437B1 (en) | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
| EP1109019A1 (en) * | 1999-12-15 | 2001-06-20 | BioStrands S.r.l. | Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease |
| AU2001233513A1 (en) * | 2000-02-04 | 2001-08-14 | K.U. Leuven Research And Development | Hiv-1 resistance assay |
| GB0009374D0 (en) * | 2000-04-14 | 2000-05-31 | Glaxo Group Ltd | Phenotyping assay and reagents therefor |
| ES2373488T3 (es) * | 2000-04-18 | 2012-02-06 | Virco Bvba | Métodos para medir la resistencia a los fármacos frente a hcv. |
| EP1276909B1 (en) * | 2000-04-20 | 2013-11-13 | Janssen Diagnostics BVBA | Method for mutation detection in hiv using pol sequencing |
| US6800463B1 (en) * | 2000-04-20 | 2004-10-05 | Virco Bvba | Method for mutation detection in HIV-1 using pol sequencing |
| US6582901B2 (en) | 2000-04-26 | 2003-06-24 | Bruce K. Patterson | Cell specific anti-viral drug susceptibility test using tagged permissive target cells |
| US7058616B1 (en) | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
| CN1446265A (zh) * | 2000-06-12 | 2003-10-01 | 病毒科学公司 | 检测抗反转录病毒治疗的方式与方法和在hiv/aids治疗中的指导治疗方案 |
| US6582920B2 (en) * | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
| WO2002033638A2 (en) | 2000-10-20 | 2002-04-25 | Virco Bvba | Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| ATE422049T1 (de) * | 2000-10-20 | 2009-02-15 | Virco Bvba | Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz |
| US6958211B2 (en) * | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
| EP1283272B1 (en) * | 2001-08-08 | 2013-11-13 | Janssen R&D Ireland | Methods and means for assessing HIV envelope inhibitor therapy |
| ES2302860T3 (es) | 2001-11-08 | 2008-08-01 | Tibotec Pharmaceuticals Ltd. | Ensayo de proteasas para la monitorizacion terapeutica de farmacos. |
| WO2004003817A1 (en) | 2002-07-01 | 2004-01-08 | Tibotec Pharmaceuticals Ltd. | Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance |
| WO2004003223A2 (en) | 2002-07-01 | 2004-01-08 | Tibotec Pharmaceuticals Ltd. | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| WO2005086061A2 (en) * | 2004-03-02 | 2005-09-15 | Virco Bvba | Estimation of clinical cut-offs |
| CA2631881C (en) | 2005-12-07 | 2015-03-24 | Tibotec Pharmaceuticals Ltd. | Methods, plasmid vectors and primers for assessing hiv viral fitness |
| EP2010680A2 (en) * | 2006-04-14 | 2009-01-07 | Tibotec Pharmaceuticals Ltd. | Methods and means for assessing hiv gag/protease inhibitor therapy |
| US20100173282A1 (en) | 2007-05-25 | 2010-07-08 | Tibotec Pharmaceuticals Ltd. | Mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance |
| AU2009301125B2 (en) * | 2008-10-06 | 2015-02-26 | Virco Bvba | Method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of Hepatitis C Virus (HCV) for genotypes 1 to 6 |
| AU2010247444A1 (en) * | 2009-05-12 | 2011-11-24 | Virco Bvba | HIV-1-C resistance monitoring |
| CN107085093B (zh) * | 2017-03-24 | 2019-06-21 | 西藏诺迪康药业股份有限公司 | 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875396A (en) | 1973-11-12 | 1975-04-01 | Illuminite Corp | Illuminated clipboard |
| US4675147A (en) * | 1983-04-06 | 1987-06-23 | Westinghouse Electic Corp. | Generating an integrated graphic display of the safety status of a complex process plant |
| US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| CA2032158C (en) | 1989-05-25 | 2009-09-15 | Helmut Bachmayer | Multivalent repressor of gene function |
| US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| JPH05148202A (ja) * | 1991-04-10 | 1993-06-15 | Tsumura & Co | 新規な化合物およびその医薬としての用途 |
| WO1993023574A1 (en) | 1992-05-14 | 1993-11-25 | Kozal Michael J | Polymerase chain reaction assays for monitoring antiviral therapy |
| US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
| EP0651825B1 (en) | 1992-07-06 | 1998-01-14 | President And Fellows Of Harvard College | Methods and diagnostic kits for determining the toxicity of a compound utilizing bacterial stress promoters fused to reporter genes |
| US5344846A (en) | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
| US6063562A (en) | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| WO1997012220A2 (en) | 1995-09-15 | 1997-04-03 | Samir Chachoua | Method for the identification and therapeutic use of disease-associated organisms, elements and forces |
| US5885806A (en) * | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
| RO118887B1 (ro) | 1996-01-29 | 2003-12-30 | Virologic, Inc. | Metodă pentru determinarea sensibilităţii sau eficacităţii biologice şi rezistenţei omului la medicamentele antivirale |
| US5837464A (en) | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US5945276A (en) | 1996-04-10 | 1999-08-31 | Signal Pharmaceuticals, Inc. | Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression |
| US5939253A (en) | 1996-04-26 | 1999-08-17 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting viral infection |
| EP1435519B1 (en) | 1997-04-07 | 2007-02-14 | Fisher BioImage ApS | A method for screening substances for effect on cAMP levels based on intracellular translocation of PKA |
| US6365347B1 (en) | 1997-04-11 | 2002-04-02 | The Regents Of The University Of California | Method for identifying disruptors of biological pathways using genetic selection |
| WO1998059074A1 (en) | 1997-06-23 | 1998-12-30 | Emory University | Human immunodeficiency viruses causing aids in a nonhuman primate |
| US5976813A (en) | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
-
1997
- 1997-01-24 ES ES97900712T patent/ES2177922T3/es not_active Expired - Lifetime
- 1997-01-24 CN CN97191904A patent/CN1209875A/zh active Pending
- 1997-01-24 PL PL97328069A patent/PL186473B1/pl not_active IP Right Cessation
- 1997-01-24 CZ CZ19982335A patent/CZ292899B6/cs not_active IP Right Cessation
- 1997-01-24 DE DE69712731T patent/DE69712731T2/de not_active Expired - Lifetime
- 1997-01-24 SK SK1002-98A patent/SK283878B6/sk not_active IP Right Cessation
- 1997-01-24 IL IL12544297A patent/IL125442A/en not_active IP Right Cessation
- 1997-01-24 WO PCT/IB1997/000071 patent/WO1997027480A1/en not_active Application Discontinuation
- 1997-01-24 AU AU13168/97A patent/AU717755B2/en not_active Ceased
- 1997-01-24 HU HU9902618A patent/HU226203B1/hu not_active IP Right Cessation
- 1997-01-24 AT AT97900712T patent/ATE217971T1/de active
- 1997-01-24 TR TR1998/01443T patent/TR199801443T2/xx unknown
- 1997-01-24 BR BR9707204-4A patent/BR9707204A/pt not_active Application Discontinuation
- 1997-01-24 EP EP97900712A patent/EP0877937B1/en not_active Expired - Lifetime
- 1997-01-24 US US09/117,217 patent/US6221578B1/en not_active Expired - Lifetime
- 1997-01-24 CN CNA2006101685069A patent/CN1991365A/zh active Pending
- 1997-01-24 KR KR10-1998-0705747A patent/KR100495690B1/ko not_active IP Right Cessation
- 1997-01-24 NZ NZ325912A patent/NZ325912A/xx not_active IP Right Cessation
- 1997-12-27 ZA ZA9700669A patent/ZA97669B/xx unknown
-
1998
- 1998-07-16 NO NO19983300A patent/NO321329B1/no not_active IP Right Cessation
- 1998-07-20 IS IS4799A patent/IS4799A/is unknown
- 1998-08-20 BG BG102710A patent/BG102710A/xx unknown
-
2000
- 2000-12-14 US US09/735,487 patent/US6528251B2/en not_active Expired - Fee Related
-
2003
- 2003-01-15 US US10/342,188 patent/US20030152917A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO321329B1 (no) | Fremgangsmate til a fastsette kjemoterapi for pasienter som er HIV positive, basert pa fenotypisk legemiddelfolsomhet hos pasientens HIV-stammer | |
| Bacheler et al. | Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy | |
| US20070134766A1 (en) | Methods of assessing hiv integrase inhibitor therapy | |
| Ambrose et al. | In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques | |
| KR20190104586A (ko) | 예비-면역화 단계가 없는 hiv 면역요법 | |
| Wapling et al. | Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer | |
| Chopera et al. | Immune-mediated attenuation of HIV-1 | |
| EP1285971A2 (en) | Methods for the phenotypic and genotypic assessment of the drug sensitivity of HIV integrase variants | |
| CA2244735C (en) | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains | |
| RU2174014C2 (ru) | Способ определения оптимальной химиотерапии пациентов, серопозитивных по вич, основанный на фенотипической лекарственной чувствительности человеческих штаммов вич | |
| Yang et al. | Human immunodeficiency virus type 2 capsid protein mutagenesis defines the determinants for Gag–Gag interactions | |
| Bagaya et al. | Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants | |
| Payne et al. | Virulence determinants of equine infectious anemia virus | |
| Yang et al. | Human immunodeficiency virus type 2 capsid protein mutagenesis reveals amino acid residues important for virus particle assembly | |
| CA2760781A1 (en) | Hiv-1-c resistance monitoring | |
| EP2010680A2 (en) | Methods and means for assessing hiv gag/protease inhibitor therapy | |
| McMichael et al. | Host genetics and viral diversity: report from a global HIV vaccine enterprise working group | |
| Megens et al. | Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits | |
| JP2002159297A (ja) | プロテアーゼ活性の測定方法 | |
| WO2015179793A1 (en) | Vectors and compositions for stable expression of antigens in mycobacteria | |
| JP2007515386A (ja) | Ｈｉｖ感染個体の治療用免疫化 | |
| Paolucci et al. | HIV-1 plasma variants encoding truncated reverse transcriptase (RT) in a patient with high RT-specific CD8+ memory T-cell response | |
| RU98116294A (ru) | Способ определения оптимальной химиотерапии пациентов, серопозитивных по вич, основанный на фенотипической лекарственной чувствительности человеческих штаммов вич | |
| Mulinge | " Impact of polymorphisms in the HIV Envelope on tropism determination and on infectivity of primary CD4+ T cells and macrophages | |
| Ensoli | Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |